SNSS stock went parabolic Thursday afternoon just days after the company announced positive drug data. SNSS announces positive data from two Phase 2 clinical trials of the Company’s lead drug candidate, voreloxin. We are expecting a gap up Friday with a short term price target of $2.10. StockPreacher.com also announces an investment report featuring Sunesis Pharmaceuticals Inc. The full repo Read More...



